HuGE Literature Finder
Records
1
-
30
| Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL. Technology in cancer research & treatment 2023 2 22 15330338231154092. Wang Yan, Ran Fei, Lin Jin, Zhang Jing, Ma D |
| The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience. Cellular and molecular biology (Noisy-le-Grand, France) 2023 2 68 (8): 202-209. Basim Najm Maysam, Jalal Sana Dlawar, Getta Hisham Ar |
| Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. Hematology reports 2022 Aug 14 (3): 265-269. Santoro Marco, Accurso Vincenzo, Mancuso Salvatrice, Napolitano Mariasanta, Mattana Marta, Vajana Giorgia, Russello Federica, Siragusa Serg |
| Lab tests for MPN. International review of cell and molecular biology 2022 2 366 187-220. Moncada Alice, Pancrazzi Alessand |
| Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). International journal of environmental research and public health 2021 Jul 18 (14): . Zulkeflee Razan Hayati, Zulkafli Zefarina, Johan Muhammad Farid, Husin Azlan, Islam Md Asiful, Hassan Rosli |
| Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. Journal of clinical medicine 2021 Mar 10 (5): . Lee Jong-Mi, Lee Howon, Eom Ki-Seong, Lee Sung-Eun, Kim Myungshin, Kim Yongg |
| [Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2021 1 41 (12): 989-995. Wu J Y, Li B, Jia Y J, Zhang P H, Xu Z F, Qin T J, Qu S Q, Pan L J, Liu J Q, Yan X, Zhang Y D, Chen J, Gong J Y, Xiao Z |
| Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges. Clinical lymphoma, myeloma & leukemia 2021 3 21 (6): e569-e578. Singh Suvir, Kaur Komalpreet, Paul Davinder, Jain Kunal, Singh Jagdeep, Narang Vikram, Garg Bhavna, Sood Neena, Dhillon Barjinderj |
| JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East. Iranian journal of pathology 2021 5 16 (2): 190-194. Safavi Moeinadin, Monabati Ahmad, Safaei Akbar, Mirtalebi Maryam Sadat, Faghih Masoum |
| Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India. Hematology/oncology and stem cell therapy 2021 3 15 (2): 13-20. Maddali Madhavi, Kulkarni Uday Prakash, Ravindra Niveditha, Arunachalam Arun Kumar, Venkatraman Arvind, Lionel Sharon, Manipadam Marie Therese, Devasia Anup J, Korula Anu, Fouzia N A, Abraham Aby, Srivastava Alok, George Biju, Balasubramanian Poonkuzhali, Mathews Vikr |
| [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 8 41 (7): 576-582. Tan Y X, Xu N, Huang J X, Wu W E, Liu L, Zhou L L, Liu X L, Yin C X, Xu D, Zhou |
| JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms. Clinical lymphoma, myeloma & leukemia 2020 6 20 (10): e645-e651. Soliman Eman A, El-Ghlban Samah, El-Aziz Sherin Abd, Abdelaleem Abdelaleem, Shamaa Sameh, Abdel-Ghaffar Hass |
| Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia 2020 6 35 (2): 468-475. Barosi Giovanni, Rosti Vittorio, Catarsi Paolo, Villani Laura, Abbà Carlotta, Carolei Adriana, Magrini Umberto, Gale Robert Peter, Massa Margherita, Campanelli Ri |
| Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematology, transfusion and cell therapy 2019 Oct . Porto-Soares Moysés Antonio, de Oliveira Rafael Daltro, Cortopassi Gabriel Macedo, Machado-Neto João Agostinho, Palma Leonardo Carvalho, Figueiredo-Pontes Lorena Lobo |
| TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients. International journal of hematology 2019 Sep . Matsuguma Masafumi, Yujiri Toshiaki, Yamamoto Kaoru, Kajimura Yasuko, Tokunaga Yoshihiro, Tanaka Mayumi, Tanaka Yoshinori, Nakamura Yukinori, Tanizawa Yuk |
| [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms]. Zhonghua nei ke za zhi 2019 12 59 (1): 35-39. Lyu X D, Li Y W, Guo Z, Xin Y P, Hu J Y, Fan R H, Song Y |
| Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 2019 2 133 (20): 2233-2242. Gagelmann Nico, Ditschkowski Markus, Bogdanov Rashit, Bredin Swann, Robin Marie, Cassinat Bruno, Shahswar Rabia, Thol Felicitas, Heuser Michael, Socié Gerard, Beelen Dietrich, Triviai Ioanna, Badbaran Anita, Kröger Nicola |
| Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis. Balkan journal of medical genetics : BJMG 2019 9 22 (1): 57-60. Nikolova D, Yordanov A, Damyanova V, Radinov A, Toncheva |
| Mutational profiling in myelofibrosis: implications for management. International journal of hematology 2019 10 111 (2): 192-199. Bose Prithviraj, Verstovsek Srd |
| Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC cancer 2019 6 19 (1): 590. Mejía-Ochoa Mónica, Acevedo Toro Paola Andrea, Cardona-Arias Jaiberth Anton |
| WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood cells, molecules & diseases 2019 1 75 35-40. Cottin Laurane, Riou Jérémie, Boyer Françoise, Bouvier Anne, Zannetti Alain, Blouet Anaïse, Truchan-Graczyk Matgorzata, Jouanneau-Courville Rébecca, Beucher Annaëlle, Ribourtout Bénédicte, Orvain Corentin, Hunault-Berger Mathilde, Blanchet Odile, Ugo Valérie, Luque Paz Dami |
| [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases]. Zhongguo shi yan xue ye xue za zhi 2018 Aug 26 (4): 1122-1128. Li Zhen-Ling, Gao Li, Zhang Hui, Zhang Chun-Xia, Chen Yan-Rong, Huang Fan-Zhou, Gong Ming, Gao Ya-Yue, Tang Yin, Ma Yi-G |
| Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. Medical oncology (Northwood, London, England) 2018 Aug 35 (9): 119. Helbig Grzego |
| GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Annals of laboratory medicine 2018 Jul 38 (4): 296-305. Yang Naery, Park Sholhui, Cho Min Sun, Lee Miae, Hong Ki Sook, Mun Yeung Chul, Seong Chu Myong, Huh Hee Jin, Huh Jungw |
| Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. International journal of hematology 2018 Feb . Misawa Kyohei, Yasuda Hajime, Araki Marito, Ochiai Tomonori, Morishita Soji, Shirane Shuichi, Edahiro Yoko, Gotoh Akihiko, Ohsaka Akimichi, Komatsu Nor |
| Classification and Personalized Prognosis in Myeloproliferative Neoplasms. The New England journal of medicine 2018 10 379 (15): 1416-1430. Grinfeld Jacob, Nangalia Jyoti, Baxter E Joanna, Wedge David C, Angelopoulos Nicos, Cantrill Robert, Godfrey Anna L, Papaemmanuil Elli, Gundem Gunes, MacLean Cathy, Cook Julia, O'Neil Laura, O'Meara Sarah, Teague Jon W, Butler Adam P, Massie Charlie E, Williams Nicholas, Nice Francesca L, Andersen Christen L, Hasselbalch Hans C, Guglielmelli Paola, McMullin Mary F, Vannucchi Alessandro M, Harrison Claire N, Gerstung Moritz, Green Anthony R, Campbell Peter |
| Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center. Neoplasma 2018 65 (2): 296-303. Palova M, Szotkowski T, Hlusi A, Indrak K, Navratilova J, Divoka M, Papajik |
| CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2017 Oct 1-4. Ojeda Mara Jorgelina, Bragós Irma Margarita, Calvo Karina Lucrecia, Williams Gladis Marcela, Carbonell María Magdalena, Pratti Arianna Flav |
| MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. American journal of hematology 2017 Oct . Trifa Adrian P, B?nescu Claudia, Bojan Anca S, Voina Cristian M, Popa ?tefana, Vi?an Simona, Ciubean Alina D, Tripon Florin, Dima Delia, Popov Viola M, Vesa ?tefan C, Andreescu Mihaela, Török-Vistai Tünde, Mih?il? Romeo G, Berbec Nicoleta, Macarie Ioan, Coli?? Andrei, Iordache Maria, C?tan? Alina C, Farca? Marius F, Tomuleasa Ciprian, Vasile Kinga, Truic? Cristina, Todinc? Adriana, Pop-Muntean Lavinia, Manolache Raluca, Bumbea Horia, Vl?d?reanu Ana-Maria, Gaman Mihaela, Ciufu Cristina M, Popp Radu |
| Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian journal of pathology & microbiology 0 61 (2): 209-213. Rabade Nikhil, Subramanian P G, Kodgule Rohan, Raval Goutham, Joshi Swapnali, Chaudhary Shruti, Mascarenhas Russel, Tembhare Prashant, Gujral Sumeet, Patkar Nikh |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 21, 2023
- Content source: